ABOUT USNCE PROJECTSNDDS PROJECTSTIMELINESINVESTORSPRESSCONTACT US


 

A brand of latanoprost, Latoprost RT has been launched in the Indian market with excellent response.

Glaucoma is a type of optic neuropathy characterized by progressive injury to the retinal ganglion cells. Elevated intraocular pressure (IOP) is considered the primary cause of the optic nerve damage.

Prostaglandin analogues such as Latanoprost are the first line treatment for glaucoma and form the largest drug class. The currently marketed Latanoprost contains a preservative, Benzalkonium Chloride (BAK). BAK not only acts as a preservative, but it also solubilizes the drug in its micellar structure and is used in almost double quantity than normally required.

However, it has been shown that on long term use, such BAK-containing eye drops may be harmful to the eye surface. EU requires replacing of BAK from eye drops wherever possible. Also, such BAK containing latanoprost drops are not stable at room temperatures, and may require storage at 2-8 degrees C.

SMM technology is a platform technology that has been developed by SPARC for solubilizing ophthalmic drugs with limited or no solubility. This technology does not require the use of quaternary ammonium preservative/surfactant like Benzalkonium Chloride which may be damaging to the eye.

Our product contains BAK-free Latanoprost. It is a patented formulation of Latanoprost with similar strength and dosing. Removal of BAK reduces tearing, burning, itching, and hence reduces drainage from the surface of the eye. Our product does not need any special refrigeration for storage/ transport.

Among all the Prostaglandin used in Glaucoma therapy, Latanoprost is the largest selling Prostaglandin with more than 60% of the volume market share. Out of this about 10-16% of the patients are likely to develop Ocular Surface Disease. So, out of these 22 million units of Prostaglandin market, Latanoprost brand and other generic will comprise about 63% and out of which our product sales are expected at about 2 million units.

We have filed an NDA in US and four select emerging markets. We are also evaluating various options of commercialization in US market and we are planning to file this product into additional 5 emerging markets.


                                                                                                   Product
   
Home
About Us
NCE Projects
NDDS Projects
Timelines
Investors
Press
Contact Us
Careers
Site Map